ST Pharm's HIV drug candidate STP0404 shows viral load reduction in Phase 2a trial

ST Pharm's Phase 2a trial for HIV-1 drug candidate STP0404 showed antiviral activity versus placebo and a generally favorable safety and tolerability profile. Final clinical study report received Oct. 3, 2026.